Tercica, Inc. company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A. Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA.

Millennium Pharmaceuticals wants to be "the" drug company for the new millennium. Its cancer drug Velcade is approved as a treatment for multiple myeloma (a type of blood cancer) and Mantle Cell Lymphoma (or MCL, an aggressive form of non-Hodgkin's lymphoma). The company has more than a dozen other candidates in the pipeline, most of them cancer-related. Millennium's oncology-focused sales force, in partnership with Johnson & Johnson subsidiary Ortho Biotech, sells the drug in the US; Ortho Biotech is responsible for sales in Europe and in other countries where Velcade is approved (except Japan, which is covered by Janssen). Takeda Pharmaceutical acquired Millennium Pharmaceuticals for $8.8 billion in 2008.

AlphaVax, Inc. company was founded in 1998 by Robert Johnston, Nancy Davis, and Jonathan Smith, AlphaVax's chief scientific officer. AlphaVax, Inc. company is developing new vaccines for cancers and infectious diseases such as HIV/AIDS, Ebola, influenza, and other viral maladies. AlphaVax relies on a proprietary alphavaccine system that genetically alters diseased cells and transforms them into a vaccine when they attempt to replicate. Its technology could be used to develop preventative vaccines and therapeutic vaccines. Its pipeline consists of early-stage candidates. AlphaVax receives funding through partnerships and grants.

Arrow Therapeutics was founded in 1998; AstraZeneca acquired the firm in 2007. Arrow Therapeutics is a pharmaceutical product discovery company that is researching new anti-infective medicines. The company's top candidate is RSV604, an antiviral molecular program to combat respiratory syncytial virus (RSV), a leading cause of respiratory infections worldwide. This candidate is currently undergoing clinical trials and has been licensed to Novartis. Other leading programs include compounds developed to fight infectious dieseases such as Hepatitis C, herpes, and chicken pox.

Pharmasset, Inc. was founded in 1998 and is based in Princeton, New Jersey. Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing novel drugs to treat viral infections. Its primary focus is on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection; and Racivir for the treatment of human immunodeficiency virus (HIV) infection. The company has three product candidates under development, which include RG7128, a HCV nucleoside polymerase inhibitor that is in Phase IIb clinical trial; PSI-7851, a HCV nucleotide polymerase inhibitor that completed Phase I clinical trial; and Racivir, which completed Phase II clinical trial, for the treatment of HIV. It has strategic collaboration agreement with F. Hoffmann-LaRoche Ltd. and Hoffmann-La Roche Inc. for the development of PSI-6130 and its products, including RG7128. The company also has collaboration and licensing agreements with University of Cincinnati; Apath, LLC; Emory University; Bukwang Pharm. Co., Ltd; University of Georgia Research Foundation, Inc. and Yale University; and Boehringer Ingelheim Chemicals, Inc.

William Ransom & Son plc is a United Kingdom-based company engaged in the supply of branded natural health products, vitamins and food supplements, the manufacture of pharmaceutical products and the extraction of plant material for the pharmaceutical, food and beverage industries. The Company operates in three divisions: consumer healthcare, pharmaceutical and natural products. Consumer healthcare includes the sale of consumer-branded healthcare products. The pharmaceutical division includes the manufacture of its own Medicines and Healthcare Products Regulatory Agency (MHRA)-licensed products, as well as pharmaceuticals and over-the-counter products for third parties. The natural products division includes the manufacture of botanical extracts used as ingredients by the pharmaceutical division and sold to third parties.

Cypress Bioscience, Inc. was founded in 1981 and is based in San Diego, California. Cypress Bioscience, Inc. provides therapeutics and personalized medicine services. The company focuses on addressing the needs of physicians and their patients by identifying unmet medical needs in the areas of pain, rheumatology, and physical medicine and rehabilitation, including challenging disorders, such as fibromyalgia and rheumatoid arthritis. It offers Savella, a dual-reuptake inhibitor that preferentially blocks the reuptake of norepinephrine for the management of fibromyalgia. The company provides personalized medicine services, which include tests that are validated analytically and clinically to provide physicians with actionable information to help manage their patients care, including predicting the likelihood of developing disease or optimizing therapy. Its personalized medicine services include Avise PG, a test that supports dose optimization and therapeutic decision making for patients taking methotrexate, a therapy for rheumatoid arthritis (RA); and Avise MCV, a test that aids in the diagnosis and prognosis of RA. The company has a license agreement with Pierre Fabre Medicament to develop and sell products with the compound milnacipran as an active ingredient for various indications in the United States and Canada; a collaboration agreement with Forest Laboratories, Inc. for the development and marketing of milnacipran; and a reformulation and new product agreement with Collegium Pharmaceutical, Inc.

Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado. Allos Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company’s lead product candidate, pralatrexate (PDX) an antifolate, is in Phase II trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company’s other product candidate is RH1, a targeted chemotherapeutic agent, which is in a Phase I trial in patients with advanced solid tumors or non-Hodgkin's Lymphoma. In February 2009, the Company announced the final results from PROPEL, its pivotal Phase II trial of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This trial was conducted under an agreement reached with the United States Food and Drug Administration (FDA) under its special protocol assessment (SPA) process.

Quarks may be the basic building blocks of matter, but it's a fundamental unit of biology -- genes -- that Quark Pharmaceuticals is interested in. The drug development company is using cutting-edge RNA interference (RNAi) technology to develop small-interfering RNA (siRNA) molecules, or drugs that inhibit targeted genes from producing proteins associated with certain diseases. Its lead product RTP801i-14, which it has licensed to Pfizer, aims to treat wet age-related macular degeneration (a cause of blindness in the elderly). Quark Pharmaceuticals is developing other candidates for ailments such as acute renal (kidney) failure, hearing loss, and dyslipidemia (a metabolic syndrome).

Targacept, Inc. was founded in 1997 and is based in Winston-Salem, North Carolina. Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of neuronal nicotinic receptors (NNR) Therapeutics for the treatment of multiple diseases and disorders of the central nervous system. The Company has clinical-stage product candidates for target indications in three therapeutic areas, which includes cognitive impairment, depression and anxiety, and pain. It also has preclinical programs focused in smoking cessation, addiction, obesity, pain, Parkinson’s disease and inflammation. The Company has collaboration with AstraZeneca and an alliance with GlaxoSmithKline. The drug discovery activities utilize computer-based molecular design methodologies and biological data for a library of compounds developed and collected over more than 20 years. The technologies are referred to as Pentad. The Company use Pentad to design or optimize AZD3480 (TC-1734), TC-5619, TC-2216 and TC-6499.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.